



MISSISSIPPI DIVISION OF
MEDICAID

**Mississippi Division Of Medicaid
Preferred Drug List Changes
P&T Meeting Date: May 12, 2015
PDL Changes Effective Date: July 1, 2015**

The following changes will be made to the Preferred Drug List (PDL), effective July 1, 2015, pending recommendation and/or approval by the P&T Committee, DOM, and DOM's Executive Director.

For a comprehensive PDL, refer to <http://www.medicaid.ms.gov/providers/pharmacy/preferred-drug-list/>.

NEW PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for PREFERRED STATUS
Acne Agents	tretinoin cream
Antipsychotics	olanzapine
Antipsychotics	ziprasidone
Antiretrovirals	EVOTAZ (atazanavir/cobicistat)
Cytokine & Cam Antagonists	COSENTYX (secukinumab)
Platelet Aggregation Inhibitors	clopidogrel

NEW NON-PREFERRED DRUGS	
THERAPEUTIC CLASS	RECOMMENDED for NON-PREFERRED STATUS
Acne Agents	ONEXTON (benzoyl peroxide/clindamycin)
Analgesics, Narcotic-Long Acting	HYSINGLA ER (hydrocodone)
Anticoagulants	SAVAYSA (edoxaban tosylate)
Antifungals (Topical)	KERYDIN (tavaborole)
Antineoplastics-Selected Systemic Enzyme Inhibitors	IBRANCE (palbociclib)
Antineoplastics-Selected Systemic Enzyme Inhibitors	LENVIMA (lenvatinib)
Antineoplastics-Selected Systemic Enzyme Inhibitors	LYNPARZA (olaparib)
Antiparkinson's Agents (oral)	RYTARY ER (levodopa/carbidopa)
Antipsychotics	GEODON (ziprasidone)
Antipsychotics	ZYPREXA (olanzapine)
Antiretrovirals	PREZCOBIX (darunavir/cobicistat)
Antiretrovirals	VITEKTA (elvitegravir)
<i>Cytokine & Cam Antagonists</i>	<i>ENBREL (etanercept)</i>
Cytokine & Cam Antagonists	RASUVO (methotrexate)
Erythropoiesis Stimulating Proteins	MIRCERA (methoxy polyethylene glycol-epoetin-beta)
Hypoglycemics, Insulins and Related Agents	AFREZZA (insulin)
Hypoglycemics, Sodium Glucose Cotransporter-2 Inhibitors	GLYXAMBI (empagliflozin/linagliptin)
Irritable Bowel Syndrome/Short Bowel Syndrome Agents/Selected GI Agents	MOVANTIK (naloxegol)
Miscellaneous Brand/Generic	BUNAVAIL (buprenorphine/naloxone)
Miscellaneous Brand/Generic	ORALAIR
Platelet Aggregation Inhibitors	PLAVIX (clopidogrel)
Sedative Hypnotics	BELSOMRA (sovorexant)



MISSISSIPPI DIVISION OF
MEDICAID

**Mississippi Division Of Medicaid
Preferred Drug List Changes
P&T Meeting Date: May 12, 2015
PDL Changes Effective Date: July 1, 2015**

NEW THERAPEUTIC CLASSES/DRUGS	
NEW THERAPEUTIC CLASS	RECOMMENDED for PREFERRED STATUS
Gaucher's Disease	ELELYSO (taliglucerase alfa)
Gaucher's Disease	ZAVESCA (miglustat)
Idiopathic Pulmonary Fibrosis	ESBRIET (pirfenidone)
Idiopathic Pulmonary Fibrosis	OFEV (nintedanib)

NEW THERAPEUTIC CLASSES/DRUGS	
NEW THERAPEUTIC CLASS	RECOMMENDED for Non-PREFERRED STATUS
Gaucher's Disease	CERDELGA (eliglustat)
Gaucher's Disease	CEREZYME (imiglucerase)
Gaucher's Disease	VPRIV (taliglucerase alfa)

For changes in red italics, only considered non-preferred for plaque psoriasis (product is preferred for all other indications); existing users will be grandfathered though June 30, 2015